300485 賽升藥業
按盤價 
15.110 +0.120 (+0.801%)
15.110 +0.120 (+0.801%) | 2025/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 92,537 | -15.52% | 416,482 | 476,570 | 734,547 | 1,050,805 | |
| 減：營業總成本 | 90,214 | -13.20% | 391,077 | 517,648 | 710,538 | 945,017 | |
| 其中:營業成本 | 34,962 | -5.92% | 140,431 | 140,939 | 171,608 | 182,124 | |
| 財務費用 | (46) | -81.71% | (1,689) | (1,049) | (451) | (11,303) | |
| 資產減值損失 | -- | -- | (2,795) | -- | 0 | -- | |
| 公允價值變動收益 | 30,377 | -120.51% | (56,509) | 100,267 | 125,409 | 185,652 | |
| 投資收益 | 16,178 | -119.50% | (51,621) | 59,807 | 86,709 | 132,783 | |
| 其中：對聯營企業和合營企業的投資收益 | 15,875 | -117.46% | (65,529) | 46,915 | 54,146 | 91,724 | |
| 營業利潤 | 47,375 | -121.05% | (82,974) | 121,736 | 254,636 | 438,999 | |
| 利潤總額 | 47,504 | -121.11% | (83,566) | 122,163 | 254,616 | 439,024 | |
| 減：所得稅費用 | 8,560 | -126.18% | (6,692) | 25,755 | 51,966 | 43,890 | |
| 淨利潤 | 38,945 | -120.25% | (76,874) | 96,408 | 202,650 | 395,134 | |
| 減：非控股權益 | (1,025) | -40.69% | (8,021) | (6,510) | (2,085) | (7,136) | |
| 股東淨利潤 | 39,970 | -120.97% | (68,853) | 102,918 | 204,735 | 402,270 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.083 | -120.98% | -0.140 | 0.210 | 0.430 | 0.840 | |
| 每股派息 (元) * | -- | -- | -- | 0.022 | 0.086 | 0.168 | |
| 每股淨資產 (元) * | 7.053 | 4.67% | 6.970 | 7.134 | 7.005 | 6.736 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 31/07/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
